Cepheid Shares Jump Nearly 18 Percent After FDA Clearance | GenomeWeb
Shares in Cepheid rose 17.8 percent for the five-day trading period ended Tuesday, following last week’s clearance by the US Food and Drug Administration of the firm’s meningitis molecular diagnostic assay. The test is Cepheid’s third molecular diagnostic product cleared by the FDA for sale in the US.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.